American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes-Reference-Cited by-同舟云学术

American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes

Published:2014-04-20 Issue:12 Volume:32 Page:1277-1280
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Ellis Lee M.¹,Bernstein David S.¹,Voest Emile E.¹,Berlin Jordan D.¹,Sargent Daniel¹,Cortazar Patricia¹,Garrett-Mayer Elizabeth¹,Herbst Roy S.¹,Lilenbaum Rogerio C.¹,Sima Camelia¹,Venook Alan P.¹,Gonen Mithat¹,Schilsky Richard L.¹,Meropol Neal J.¹,Schnipper Lowell E.¹

Affiliation:

1. Lee M. Ellis, University of Texas MD Anderson Cancer Center, Houston, TX; David S. Bernstein and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Emile E. Voest, University Medical Center Utrecht, Utrecht, the Netherlands; Jordan D. Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN; Daniel Sargent, Mayo Clinic, Rochester, MN; Patricia Cortazar, US Food and Drug Administration, Silver Spring, MD; Elizabeth Garrett-Mayer, Medical University of South Carolina, Charleston, SC;...

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2013.53.8009

Reference27 articles.

1. Inhibiting the Hedgehog Pathway in Patients with the Basal-Cell Nevus Syndrome

2. Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma

3. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

4. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

5. Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Cited by 353 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2− and HER2+ metastatic breast cancer;Breast Cancer Research and Treatment;2024-08-23

2. Towards Treatment Effect Interpretability: A Bayesian Re-analysis of 194,129 Patient Outcomes Across 230 Oncology Trials;2024-07-24

3. A Nomogram Including Sarcopenia for Predicting Progression-Free Survival in Patients with Localized Papillary Renal Cell Carcinoma: A Retrospective Cohort Study;Annals of Surgical Oncology;2024-07-01

4. Bayesian Interim Analysis and Efficiency of Phase III Randomized Trials;2024-06-28

5. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial;BMJ;2024-05-28